Kate Traynor. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh： See more » Drug ApprovalDrug Therapy, CombinationGenotypeHepatitis C, Chronic/drug therapyHepatitis C, Chronic/geneticsHumansInterferons/adverse effectsInterferons/therapeutic useRibavirin/therapeutic useSofosbuvirUnited StatesUnited States Food and Drug AdministrationUridine Monophosphate/administration & dosageUridine Monophosphate/analogs & derivativesUridine Monophosphate/therapeutic use
Substances： See more » RibavirinInterferonsUridine MonophosphateSofosbuvir
Year: 2014 PMID： 24375596 DOI： 10.2146/news140006
Source DB: PubMed Journal: Am J Health Syst Pharm ISSN： 1079-2082 Impact factor: 2.637